Credit Suisse Ag Cassava Sciences Inc Call Options Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SAVA
# of Institutions
172Shares Held
11.3MCall Options Held
1.61MPut Options Held
1.43M-
Black Rock Inc. New York, NY3.05MShares$31.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.36MShares$24.1 Million0.0% of portfolio
-
State Street Corp Boston, MA1.09MShares$11.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA902KShares$9.22 Million0.0% of portfolio
-
Gallacher Capital Management LLC Lone Tree, CO585KShares$5.98 Million6.03% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $410M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...